anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Zepatier
Trial phase: Phase 4
ATC code: J05AP54
SMILES: C=CC1CC1(NC(=O)C1CC2CN1C(=O)C(C(C)(C)C)NC(=O)OC1CC1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1.COC(=O)NC(C(=O)N1CCCC1c1ncc(-c2ccc3c(c2)cc2n3C(c3ccccc3)Oc3cc(C4=NC(C5CCCN5C(=O)C(NC(=O)OC)C(C)C)N=C4)ccc3-2)[nH]1)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 25
Group description: 25 People Who Inject Drugs engaged in a Needle Exchange Program with risk reduction education, treated for their HCV using elbasvir-grazoprevir (50 mg/100 mg) for 12 weeks.

elbasvir-grazoprevir (50 mg/100 mg): 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
Eligibility criteria:
Inclusion Criteria:

Genotype 1b and genotype 1a without baseline NS5A resistance or Genotype 4
APRI Score <0.7; if >0.7 a Fibrosure/Fibrotest or Fibroscan score of F2 or less
No clinical or laboratory evidence of cirrhosis
Readiness for treatment based on ability to make >2/3 sequential office visits
Patients must be assessed to have decision-making capacity, be capable of consenting, and not be displaying evidence of overt intoxication.

Exclusion Criteria:

Clinical or Laboratory Evidence of Cirrhosis
Elevated prothrombin time unrelated to anticoagulation, hemoglobin level less than 12.3 g/L in females and <14 g/L in males, platelet count <150 × 109 cells/L), white blood cells (WBC) <4.0 x103/mm3 , aminotransferase levels more than 10 times the upper limit of normal, or albumin level <3.5 g/L.
Previous treatment for hepatitis C infection
Hepatocellular carcinoma
HIV or hepatitis B virus co-infection
Subjects taking medications that are contra-indicated to administer with Zepatier including phenytoin, carbamazepine, rifampin, St. John's Wort, and cyclosporine AND unable to change these medications to one without interactions.
Intervention: Betamethasone Sodium Phosphate
Trial phase: Phase 2
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: TLC399 (ProDex) 0.36mg DSP with 100 mM PL

TLC399 (ProDex): 2-vial system: TLC399-DSP and TLC399-Lipid
Eligibility criteria:
Inclusion Criteria:

male or female, at least 18 years of age
macular edema due to CRVO or BRVO
best-corrected visual acuity (BCVA) score of 20/40 to 20/400
mean central subfield thickness (CST) ≥350 um
willing and able to comply with the study procedure and sign a written informed consent
agree to use a medically acceptable form of birth control

Exclusion Criteria:

poorly controlled diabetes
history of significant intraocular pressure (IOP) elevation to steroid treatment
history of ocular hypertension and glaucoma
cataract surgery in the study eye within 3 months, or intraocular surgery within 6 months prior to screening
use of hemodilution for the treatment of RVO
use of IVT ranibizumab or bevacizumab in the study eye within 6 weeks prior to screening; or IVT aflibercept within 8 weeks prior to screening
IVT Ozurdex to the study eye within 6 months prior to screening
prior use of Retisert or Iluvien
use of systemic steroids or heparin within 1 month prior to screening
Intervention: Betamethasone Sodium Phosphate
Trial phase: Phase 2
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: TLC399 (ProDex) 0.6 mg DSP with 100 mM PL

TLC399 (ProDex): 2-vial system: TLC399-DSP and TLC399-Lipid
Eligibility criteria:
Inclusion Criteria:

male or female, at least 18 years of age
macular edema due to CRVO or BRVO
best-corrected visual acuity (BCVA) score of 20/40 to 20/400
mean central subfield thickness (CST) ≥350 um
willing and able to comply with the study procedure and sign a written informed consent
agree to use a medically acceptable form of birth control

Exclusion Criteria:

poorly controlled diabetes
history of significant intraocular pressure (IOP) elevation to steroid treatment
history of ocular hypertension and glaucoma
cataract surgery in the study eye within 3 months, or intraocular surgery within 6 months prior to screening
use of hemodilution for the treatment of RVO
use of IVT ranibizumab or bevacizumab in the study eye within 6 weeks prior to screening; or IVT aflibercept within 8 weeks prior to screening
IVT Ozurdex to the study eye within 6 months prior to screening
prior use of Retisert or Iluvien
use of systemic steroids or heparin within 1 month prior to screening
Intervention: Cholecalciferol
Trial phase: Phase 3
ATC code: A11CC05 | A11CC55 | M05BB03 | M05BB04 | M05BB05 | M05BB07 | M05BB08 | M05BB09 | M05BX53
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)CCC1=C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 690
Group description: A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.

Vitamin D3: 540,000 IU vitamin D3
Eligibility criteria:
Inclusion Criteria:

Age ≥ 18 years
Intention to admit to ICU from emergency department, hospital ward, operating room, or outside facility

One or more of the following acute risk factors for ARDS and mortality contributing directly to the need for ICU admission:

Pulmonary

Pneumonia
Aspiration
Smoke Inhalation
Lung contusion
Mechanical ventilation for acute hypoxemic or hypercarbic respiratory failure Extra-Pulmonary
Shock
Sepsis
Pancreatitis
Vitamin D deficiency (screening 25OHD level <20 ng/mL)

Exclusion Criteria:

Inability to obtain informed consent
Unable to randomize within 12 hours of ICU admission decision
Unable to take study medication by mouth or enteral tube
Baseline serum calcium >10.2 mg/dL (2.54 mmol/L) or ionized calcium >5.2 mg/dL (1.30 mmol/L)
Known kidney stone in past year or history of multiple (>1) prior kidney stone episodes
Decision to withhold or withdraw life-sustaining treatment (patients are still eligible if they are committed to full support except cardiopulmonary resuscitation if a cardiac arrest occurs)
Expect <48 hour survival
If no other risk factors present, a) mechanical ventilation primarily for airway protection, pain/agitation control, or procedure; or b) elective surgical patients with routine postoperative mechanical ventilation; or c) anticipated mechanical ventilation duration <24 hours; or d) chronic/home mechanical ventilation for chronic lung or neuromuscular disease (non-invasive ventilation used solely for sleep-disordered breathing is not an exclusion).
Prisoner
Pregnancy
Intervention: Lubiprostone
Trial phase: Phase 3
ATC code: A06AX03
SMILES: [H][C@@]12CC(=O)[C@H](CCCCCCC(=O)O)[C@@]1([H])CC[C@](O)(C(F)(F)CCCC)O2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 275
Group description: Lubiprostone 24 mcg sprinkle BID for 7 days.
Eligibility criteria:
Inclusion Criteria:

Either has medically-confirmed diagnosis of chronic constipation (per Rome III), or meets the diagnosis as confirmed using the Rome III constipation module questionnaire during the Screening period.
Is male or female, 18 or older years of age
Should be on stable dose of fiber supplement or a concomitant medication for the indication of lowering blood pressure

Exclusion Criteria:

Has any gastrointestinal (GI) condition, other than constipation, affecting GI motility or defecation
Is unable to eat or drink, take oral medications, or to hold down oral medications due to vomiting
Intervention: Lubiprostone
Trial phase: Phase 3
ATC code: A06AX03
SMILES: [H][C@@]12CC(=O)[C@H](CCCCCCC(=O)O)[C@@]1([H])CC[C@](O)(C(F)(F)CCCC)O2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 130
Group description: Lubiprostone 24 mcg capsule BID for 7 days.
Eligibility criteria:
Inclusion Criteria:

Either has medically-confirmed diagnosis of chronic constipation (per Rome III), or meets the diagnosis as confirmed using the Rome III constipation module questionnaire during the Screening period.
Is male or female, 18 or older years of age
Should be on stable dose of fiber supplement or a concomitant medication for the indication of lowering blood pressure

Exclusion Criteria:

Has any gastrointestinal (GI) condition, other than constipation, affecting GI motility or defecation
Is unable to eat or drink, take oral medications, or to hold down oral medications due to vomiting
Intervention: Ofloxacin
Trial phase: Not Applicable
ATC code: A02BD10 | J01MA01 | J01MA12 | J01RA05 | J01RA09 | S01AE01 | S01AE05 | S02AA16
SMILES: CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: 1 750mg tab of levofloxacin by mouth for 5 days

Levofloxacin: 5 days of levofloxacin administration
Eligibility criteria:
Inclusion Criteria:

Healthy adults ages 21-60 residing in the St. Louis, Missouri, USA metropolitan area

Exclusion Criteria:

History of allergic reaction to study antimicrobial(s)
Contraindication(s) to study antimicrobial(s)
Inability to provide regular stool samples
Any non-topical antimicrobial exposure in previous 6 months
Tube feeds as primary source of nutrition in previous 6 months
Pregnant or risk of becoming pregnant during study period
Breastfeeding during study period
Gastroenteritis in last 3 months
Any non-elective hospitalization in the previous 12 months
Incontinent of stool
Known colonization with an MDRO
Anticipated change in diet or medications during study period
Elective surgery during study period
History of an intestinal disorder
Inability to provide written, informed consent
Intervention: Azithromycin
Trial phase: Not Applicable
ATC code: J01FA10 | J01RA07 | J01RA16 | S01AA26
SMILES: CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)CN(C)C(C)C(O)C1(C)O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: 1 500mg tab by mouth on day 1, then 1 250 mg tab per day by mouth for 4 days (total 5 days)

Azithromycin: 5 days of azithromycin administration
Eligibility criteria:
Inclusion Criteria:

Healthy adults ages 21-60 residing in the St. Louis, Missouri, USA metropolitan area

Exclusion Criteria:

History of allergic reaction to study antimicrobial(s)
Contraindication(s) to study antimicrobial(s)
Inability to provide regular stool samples
Any non-topical antimicrobial exposure in previous 6 months
Tube feeds as primary source of nutrition in previous 6 months
Pregnant or risk of becoming pregnant during study period
Breastfeeding during study period
Gastroenteritis in last 3 months
Any non-elective hospitalization in the previous 12 months
Incontinent of stool
Known colonization with an MDRO
Anticipated change in diet or medications during study period
Elective surgery during study period
History of an intestinal disorder
Inability to provide written, informed consent
Intervention: Cefpodoxime
Trial phase: Not Applicable
ATC code: J01DD13
SMILES: COCC1=C(C(=O)O)N2C(=O)C(NC(=O)C(=NOC)c3csc(N)n3)C2SC1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 20
Group description: 200mg tab by mouth twice per day for 5 days

Cefpodoxime: 5 days of cefpodoxime administration
Eligibility criteria:
Inclusion Criteria:

Healthy adults ages 21-60 residing in the St. Louis, Missouri, USA metropolitan area

Exclusion Criteria:

History of allergic reaction to study antimicrobial(s)
Contraindication(s) to study antimicrobial(s)
Inability to provide regular stool samples
Any non-topical antimicrobial exposure in previous 6 months
Tube feeds as primary source of nutrition in previous 6 months
Pregnant or risk of becoming pregnant during study period
Breastfeeding during study period
Gastroenteritis in last 3 months
Any non-elective hospitalization in the previous 12 months
Incontinent of stool
Known colonization with an MDRO
Anticipated change in diet or medications during study period
Elective surgery during study period
History of an intestinal disorder
Inability to provide written, informed consent
Intervention: Licogliflozin
Trial phase: Phase 2
SMILES: CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: LIK066 10mg qd (once daily) dosing frequency for 24 weeks
Eligibility criteria:
Inclusion Criteria:

informed consent
(BMI>=30) or (BMI>=27 with history of CV disease, hypertension, dyslipidemia, pre-diabetes or type 2 diabetes mellitus, sleep-apnea syndrome)
willing to comply with life-style intervention and treatment during the full duration of the study (approximately 54 weeks)

Exclusion Criteria:

Hypersensitivity to any of the study medications
Pregnancy or lactating women
History of malignancies
Use of pharmacologically active weight loss products
Bariatric surgery
Ketoacidosis, lactic acidosis, hyperosmolar coma in the 6 months before the screening visit.
HbA1c >10% at the screening visit.
Intervention: Licogliflozin
Trial phase: Phase 2
SMILES: CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 38
Group description: LIK066 50mg qd (once daily) dosing frequency for 24 weeks
Eligibility criteria:
Inclusion Criteria:

informed consent
(BMI>=30) or (BMI>=27 with history of CV disease, hypertension, dyslipidemia, pre-diabetes or type 2 diabetes mellitus, sleep-apnea syndrome)
willing to comply with life-style intervention and treatment during the full duration of the study (approximately 54 weeks)

Exclusion Criteria:

Hypersensitivity to any of the study medications
Pregnancy or lactating women
History of malignancies
Use of pharmacologically active weight loss products
Bariatric surgery
Ketoacidosis, lactic acidosis, hyperosmolar coma in the 6 months before the screening visit.
HbA1c >10% at the screening visit.
Intervention: Licogliflozin
Trial phase: Phase 2
SMILES: CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 77
Group description: LIK066 150mg qd (once daily) dosing frequency for 24 weeks
Eligibility criteria:
Inclusion Criteria:

informed consent
(BMI>=30) or (BMI>=27 with history of CV disease, hypertension, dyslipidemia, pre-diabetes or type 2 diabetes mellitus, sleep-apnea syndrome)
willing to comply with life-style intervention and treatment during the full duration of the study (approximately 54 weeks)

Exclusion Criteria:

Hypersensitivity to any of the study medications
Pregnancy or lactating women
History of malignancies
Use of pharmacologically active weight loss products
Bariatric surgery
Ketoacidosis, lactic acidosis, hyperosmolar coma in the 6 months before the screening visit.
HbA1c >10% at the screening visit.
Intervention: Lovenox
Trial phase: Early Phase 1
SMILES: CC(=O)NC1C(O)OC(COS(=O)(=O)O)C(OC2OC(C(=O)O)C(OC3OC(CO)C(OC4OC(C(=O)O)C(O)C(O)C4OS(=O)(=O)O)C(OS(=O)(=O)O)C3NS(=O)(=O)O)C(O)C2OS(=O)(=O)O)C1O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Open-label low-molecular-weight heparin (LMWH) prophylaxis until 37 weeks gestation AND low-dose aspirin daily until delivery.

Low-molecular-weight heparin: The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.
Eligibility criteria:
Inclusion Criteria:

Confirmed pregnancy;
18 years or older;
Two or more unexplained pregnancy loss before the 10th week of gestation, AND/OR one or more unexplained pregnancy loss at or beyond the 10th week of gestation;
One or more APS laboratory criteria present, according to the revised Sapporo criteria;

Exclusion Criteria:

Greater than 11 weeks +6 days gestational age at time of randomization;
Indication(s) for prophylactic or therapeutic-dose anticoagulation;
Contraindication to heparin or aspirin;
Received 7 or more doses of LMWH;
Previous participation in the trial;
Geographic inaccessibility;
Refused consent.
Intervention: ASPIRIN
Trial phase: Early Phase 1
ATC code: A01AD05 | B01AC06 | B01AC56 | C07FX02 | C07FX03 | C07FX04 | C10BX01 | C10BX02 | C10BX04 | C10BX05 | C10BX06 | C10BX08 | C10BX12 | M01BA03 | N02AJ02 | N02AJ07 | N02AJ18 | N02BA01 | N02BA51 | N02BA71
SMILES: CC(=O)Oc1ccccc1C(=O)O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: Open-label low-dose Aspirin 81 mg daily from randomization until delivery.

Aspirin 81 mg: Aspirin 81 mg po daily in tablet form.
Eligibility criteria:
Inclusion Criteria:

Confirmed pregnancy;
18 years or older;
Two or more unexplained pregnancy loss before the 10th week of gestation, AND/OR one or more unexplained pregnancy loss at or beyond the 10th week of gestation;
One or more APS laboratory criteria present, according to the revised Sapporo criteria;

Exclusion Criteria:

Greater than 11 weeks +6 days gestational age at time of randomization;
Indication(s) for prophylactic or therapeutic-dose anticoagulation;
Contraindication to heparin or aspirin;
Received 7 or more doses of LMWH;
Previous participation in the trial;
Geographic inaccessibility;
Refused consent.
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2 | Phase 3
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 70
Group description: Saline Group:

The control group, 80 patients, will be injected with 1 ml normal saline one day following penile colour Doppler assessment.

Normal saline: The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.
Eligibility criteria:
Inclusion Criteria:

70 males will be included in the study recruited from Andrology, Sexology & STD's outpatient clinic, Kasr El Aini Hospitals, Cairo University, complaining of ED.
Unable to develop erections sufficient for intercourse.
Failing to respond to first line and second line treatments for Erectile Dysfunction with surgery as the only remaining treatment option.
Age between 18 to 80 years.

Exclusion Criteria:

- Significant cardiovascular disease interfering with sexual activity
Intervention: Cannabidiol
Trial phase: Phase 1
ATC code: N03AX24
SMILES: C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Epidiolex

Cannabidiol: Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.
Eligibility criteria:
Inclusion Criteria:

Age range 18-65 years
DSM 5 diagnosis of cannabis use disorder, based on the Structured Clinical Interview for DSM 5 (SCID-5)
Express a desire to quit cannabis use within the next 30 days
Have used cannabis on ≥4 days within the past 30 days (i.e., an average of ≥1 day per week)
For women of childbearing age, a negative pregnancy test at screening with agreement to use adequate contraception to prevent pregnancy and monthly pregnancy tests; for men, contraception will be discussed at the beginning of the study with the study physician
Consent for us to communicate with their prescribing clinician
Furnish the names of 2 locators, who would assist study staff in locating them during the study period
Live close enough to McLean Hospital to attend study visits
Plan to stay in the Boston area for the next 3 months
Are willing and able to sign informed consent

Exclusion Criteria:

Current diagnosis of other drug or alcohol dependence (excluding nicotine)
Recent (within 3 months) significant cardiac disease
Current serious psychiatric illness or history of psychosis, schizophrenia, bipolar type I disorder
Current medical condition (including significant laboratory abnormalities, such as abnormal liver function tests) that could prevent regular study attendance
Mental retardation or organic mental disorder
Acutely dangerous or suicidal behavior
Currently in a residential treatment setting in which substance use is monitored and restricted, since the restricted access to drugs could represent an important confounding variable
Pregnant, nursing, or, if a woman of childbearing potential, not using a form of birth control judged by the investigator to be effective
Concomitant daily treatment with opioid analgesics, sedative hypnotics, or other known CNS depressants
Known hypersensitivity to cannabinoids or sesame oil
Disease of the gastrointestinal system, liver, or kidneys that may impede metabolism or excretion of CBD
Inability to read or write in English
History of seizures, head trauma or other history of CNS insult that could predispose the subject to seizures
Currently taking valproic acid, lamotrigine, or propranolol, medication metabolized by UGT1A9 or UGT2B7 enzymes (CBD may affect these UGT levels)
Intervention: Lidocaine
Trial phase: Phase 3
ATC code: C01BB01 | C05AD01 | D04AB01 | N01BB02 | N01BB52 | R02AD02 | S01HA07 | S02DA01
SMILES: CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 23
Group description: Patients randomized into the lidocaine group will receive 10 mL of 1% lidocaine

1% Lidocaine: 10 mL of 1% lidocaine
Eligibility criteria:
Inclusion Criteria:

Pregnant patients over the age of 19 who are scheduled for an induction of labor and request an epidural are eligible for the study

Exclusion Criteria:

age <19
allergy to the drug or drug class
preexisting neuropathy
history of back pain prior to pregnancy or history of back surgery
history of chronic opioid use
history of hypertension or hypertensive disorders of pregnancy
congenital or acquired cardiac disease
contraindication to epidural placement (patient refusal, severe coagulopathy, infection at site of epidural needle insertion, severe hypovolemia)
Intervention: Bupivacaine
Trial phase: Phase 3
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 25
Group description: Patients randomized into the bupivacaine group will receive 10 mL of 0.25% bupivacaine

0.25% Bupivacaine: 10 mL of 0.25% bupivacaine
Eligibility criteria:
Inclusion Criteria:

Pregnant patients over the age of 19 who are scheduled for an induction of labor and request an epidural are eligible for the study

Exclusion Criteria:

age <19
allergy to the drug or drug class
preexisting neuropathy
history of back pain prior to pregnancy or history of back surgery
history of chronic opioid use
history of hypertension or hypertensive disorders of pregnancy
congenital or acquired cardiac disease
contraindication to epidural placement (patient refusal, severe coagulopathy, infection at site of epidural needle insertion, severe hypovolemia)
Intervention: Bupivacaine plus lidocaine
Trial phase: Phase 3
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.CCN(CC)CC(=O)Nc1c(C)cccc1C
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 23
Group description: Patients randomized into the bupivacaine group will receive 5 mL of 0.25% bupivacaine and 5 mL of 1% lidocaine.

Bupivacaine plus Lidocaine: 5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine
Eligibility criteria:
Inclusion Criteria:

Pregnant patients over the age of 19 who are scheduled for an induction of labor and request an epidural are eligible for the study

Exclusion Criteria:

age <19
allergy to the drug or drug class
preexisting neuropathy
history of back pain prior to pregnancy or history of back surgery
history of chronic opioid use
history of hypertension or hypertensive disorders of pregnancy
congenital or acquired cardiac disease
contraindication to epidural placement (patient refusal, severe coagulopathy, infection at site of epidural needle insertion, severe hypovolemia)